临床医学工程2024，Vol.31Issue(8)：941-942,2.DOI:10.3969/j.issn.1674-4659.2024.08.0941
不同亮丙瑞林对激素受体阳性乳腺癌患者的疗效和安全性比较
Comparison on the Efficacy and Safety of Different Leuprorelin in Patients with Hormone Receptor-Positive Breast Cancer
李炳煌 1许文叹 1杨长安 2叶泽毅 2颜少伟 1李春宝1
作者信息
- 1. 晋江市医院 (上海市第六人民医院福建医院) 药学部,福建泉州 362200
- 2. 晋江市医院 (上海市第六人民医院福建医院) 甲状腺乳腺、整形美容外科,福建泉州 362200
- 折叠
摘要
Abstract
Objective To compare the effects and safety of different leuprorelin in the treatment of patients with hormone receptor-positive breast cancer.Methods The clinical data of 132 patients with hormone receptor-positive breast cancer admitted to our hospital from January 1,2018 to December 31,2020 were retrospectively analyzed.According to the different use of leuprolide,all patients were divided into Enantone(1M)group(n=77),Enantone(3M)group(n=24)and Boennuokang(1M)group(n=31).The disease-free survival rate and incidence of adverse reactions were compared among the three groups.Results No significant difference was found in the 1-year,2-year and 3-year disease-free survival rates,and the incidence of adverse reactions among the three groups(P>0.05).Conclusions The efficacy and safety of Enantone 1M dosage form,Enantone 3M dosage form and Boennuokang 1M dosage form show no obvious difference.Different leuprolide can be selected according to patients'needs and compliance.关键词
亮丙瑞林/激素受体阳性乳腺癌/疗效/安全性Key words
Leuprorelin/Hormone receptor-positive breast cancer/Efficacy/Safety分类
医药卫生引用本文复制引用
李炳煌,许文叹,杨长安,叶泽毅,颜少伟,李春宝..不同亮丙瑞林对激素受体阳性乳腺癌患者的疗效和安全性比较[J].临床医学工程,2024,31(8):941-942,2.
